Walgreens partners with Boehringer Ingelheim for clinical trials

Walgreens has partnered with Boehringer Ingelheim to conduct a Phase III clinical trial for Survodutide, a drug targeting obesity and metabolic dysfunction-associated steatohepatitis (MASH). This marks Walgreens' first major pharmaceutical collaboration, focusing on diversifying trial populations. The trial will utilize Walgreens' pharmacy locations to recruit and manage participants, enhancing access to diverse communities.